Bellevue Healthcare Trust portfolio update

Bellevue Healthcare Trust PLC
24 April 2023
 

Logo, company name Description automatically generated

 

Bellevue Healthcare Trust have launched new video content with Doceo.

Bellevue Healthcare Trust intends to invest in a concentrated portfolio of listed or quoted equities in the global healthcare industry. The investable universe for the fund is the global healthcare industry including companies within industries such as pharmaceuticals, biotechnology, medical devices and equipment, healthcare insurers and facility operators, information technology (where the product or service supports, supplies or services the delivery of healthcare), drug retail, consumer healthcare and distribution.

The Bellevue Healthcare Trust has concentrated its holdings in recent months, but the turnover remains particularly low relative to the trust's history. Paul Major explains that the stark valuation disconnect in markets has reaffirmed the managers' belief that the holdings are compelling, and that the trust remains well placed to benefit from a normalisation in markets. Paul highlights a core holding, Sarepta Therapeutics, as a company at the forefront of gene therapy making headway in the healthcare space.

 



 

 

 For further information on Doceo please visit www.doceo.tv or contact the team on info@doceo.tv

 

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100